Novo NordiskSee all their emails

Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026

A real announcement email from Novo Nordisk. Captured November 6, 2026.

Make this email yours

Migma AI designs one like it with your logo, colors, and images.

Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026 email from Novo Nordisk screenshot

Captured Announcement

Novo Nordisk shares real-world data linking Wegovy 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at AASLD 2026.

Standard corporate press release format with top brand logo, key bullet takeaways, narrative clinical summary, two dense statistical data tables, media contacts, and citation references.

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.